Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
vFtf6UdJcKdEAdj4
Listen
